We recently looked at Goldman Sachs’ Stocks With Highest Consensus Returns: 42 Stocks With The Highest Consensus ROE. In this ...

Gilead Sciences, the maker of a twice-a-year anti-HIV injection, has approached South Africa’s medicine regulator to discuss ...

Gilead Sciences, Inc. GILD and partner Merck MRK announced new results from a mid-stage study evaluating the investigational ...

We recently made a list of Goldman Sachs’ List Of Stocks Popular With Mutual Fund Managers: Top 20 Stocks. In this piece, we ...

The second of two pivotal studies of a six-monthly HIV prevention injection containing the antiretroviral drug lenacapavir ...

Oct 2 (Reuters) - Gilead Sciences (GILD.O ... In the U.S., the drug is approved for multi-drug resistant HIV and sold under the brand "Sunlenca" for an annual list price of $42,250 per year.

In June, we heard what could be this year's biggest HIV breakthrough: a twice-yearly injection can prevent HIV infection. Findings from a second large study of the jab has now confirmed that it works.

On October 8, 2024, PhRMA held a media briefing to address growing concerns over the Inflation Reduction Act (IRA) and its effects on the biopharmaceutical industry, Medicare Part D beneficiaries, and ...

Gilead Sciences said on Wednesday it has granted royalty-free licenses to six generic drug manufacturers to make and sell ...

Lenacapavir is already in use as a treatment for HIV. However, pharma giant Gilead has been testing it as an injectable form ...

This year has seen a double dose of optimism in the field of HIV prevention. First, on 20 June 2024, came the results of the Purpose-1 trial in South Africa and Uganda.1 This randomised controlled ...